

Amendments to the Claims:

Please amend claims 1 and 9-10. Please cancel claims 2 and 6. Please add new claims 24-29. Following entrance of this amendment, claims 1, 6, 9-10 and 24-29 will be pending and under consideration.

The amendments to claims 1 and 2 find support throughout the specification, e.g., on pages 3-4. The amendments to claims 9-10 avoid double inclusion of the delivery agent. New claims 24-29 find support in the original claims and in the specification on, e.g., pages 3-4.

This listing of claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims:

Claim 1. (Currently amended): A method of treating osteoarthritis in a human in need thereof comprising orally administering to said human a pharmaceutical composition comprising between 0.4 and 2.5 mg ~~1.2 mg~~ of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoyl]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof.

Claims 2-5. (Canceled).

Claim 6. (Previously Presented): The method according to claim 1, wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable pH-lowering agent, at least one absorption enhancer, and an enteric coating.

Claim 7-8. (Canceled)

Claim 9. (Currently Amended): The method according to ~~claim 6~~ claim 1, ~~wherein the~~ whereas ~~said pharmaceutical composition comprises a delivery agent~~ is a disodium salt of 5-CNAC, a disodium salt of SNAD ~~and or~~ or a disodium salt of SNAC.

Claim 10. (Currently Amended): The method according to claim 9, ~~wherein the~~ whereas ~~said pharmaceutical composition comprises a delivery agent~~ is in micronized form.

Claims 11-16. (Canceled)

Claim 17. (Withdrawn): A pharmaceutical composition comprising between 0.4 and 2.5 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of 5-CNAC, SNAD, SNAC and disodium salts thereof together with one or more pharmaceutically acceptable diluents or carriers therefore.

Claim 18. (Withdrawn): A pharmaceutical combination comprising:

- a) between 0.4 and 2.5 mg of salmon calcitonin in free or salt form and a delivery agent selected from the group consisting of 5-CNAC, SNAD, SNAC and disodium salts thereof, and
- b) a bone resorption inhibitor, bone forming drug or pain reducing agent.

Claim 19-23. (Canceled)

Claim 24. (New) The method according to claim 1, wherein the pharmaceutical composition comprises between 0.8 and 1.2 mg of salmon calcitonin.

Claim 25. (New) The method according to claim 24, wherein the delivery agent is selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD and a disodium salt of SNAC.

Claim 26. (New) The method according to claim 25, wherein the delivery agent is a disodium salt of 5-CNAC.

Claim 27. (New) The method according to claim 24, wherein the pharmaceutical composition comprises about 1 mg of salmon calcitonin.

Claim 28. (New) The method according to claim 27, wherein the delivery agent is selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD and a disodium salt of SNAC.

Claim 29. (New) The method according to claim 28, wherein the delivery agent is a disodium salt of 5-CNAC.